

Fund house overview

A leading alternative asset management company focused on generating superior risk-adjusted alpha, with **assets under management of INR 19,200 crore (USD 2.0bn)**. Our vision is to build a world class asset management platform respected for its Excellence, Scale, and Culture. Our mission is to invest capital in the best risk-reward opportunities.

Strategy features

- **Multi-cap portfolio that captures long-term trends across five mega sectors – BFSI, Manufacturing, Consumption, Services Export, and Infrastructure - capturing the India growth story.**
- Focus on companies with sustainable business models, strong management & governance and a large opportunity size.
- Well diversified across sectors with a **25-30 stocks portfolio** with a unique & unconventional blend of **accelerated growth ("Magic") & sustainable growth ("Compounder") companies.**
- Investment style - "Quality Growth at a Reasonable Price (QGARP)"
- Risk managed through our unique & proprietary **forensic framework** - "CLEAR"

Performance since inception (6+ years track record) (%)


Period	1M	3M	6M	1Yr	2Yr	3Yr	5Yr	SI Absolute	SI TWRR
Capital Compounder Strategy	3.0%	11.8%	12.6%	16.1%	12.4%	22.8%	17.5%	263.7%	19.6%
BSE 500 TRI	2.2%	3.8%	2.0%	3.0%	0.4%	11.9%	12.3%	175.3%	15.1%
Alpha Over BSE 500 TRI	0.8%	8.1%	10.6%	13.2%	11.9%	10.9%	5.2%	88.4%	4.5%

INR 100 invested in Carnelian Capital Compounder Strategy in May 2019 is now worth ~INR 364 v/s ~INR 275 in BSE 500 TRI

Note:

Performance as on 31-07-2026. Inception: 15-05-2019. Returns >1 year are annualised. Actual performance across investors may vary. Benchmark changed to BSE 500 TRI per SEBI circular no: SEBI/HO/IMD-PoD-2/CIR/2022/172 dated 16 Dec'22. Returns calculated on a TWRR basis, net of fees and expenses, and are not verified by regulatory authorities.

Market cap allocation



Sector allocation

Sector Name	Weight
Pharma & CDMO	29.9%
BFSI - Credit	16.3%
BFSI - Non Credit	11.2%
Consumption	9.5%
Engineering & Capital Goods	9.5%
IT	8.6%
Auto & Auto Ancillary	7.6%
Hospitals	3.7%
Telecommunications	1.2%

Major holdings

Company Name	Weight
Aditya Birla Capital	10.2%
Laurus Labs	8.6%
Biocon	7.5%
ONE 97 Communications	4.6%
BHEL	4.3%
Star Health	4.2%
ICICI Bank	3.8%
Larsen & Toubro	3.7%
Yatharth Hospital	3.7%
Dr. Lal Pathlabs	3.4%

New entrants - Sun Pharma, Kalyan Jewellers, Bharti Airtel
Exits - Bandhan Bank, Pidilite, Delhivery

Portfolio attributes

Attributes	Strategy	BSE 500
Revenue CAGR FY26-28	16.4	13.4
EPS CAGR FY26-28	26.9	16.0
Portfolio PE FY28	29.6	19.7
Net debt/Equity	0.0	0.6
ROE (FY28)	18.1	14.2
PEG (FY28)	1.1	1.2
Dividend Yield% - TTM	0.7	1.1
Portfolio Beta (SI)	1.0	1.0
Sharpe Ratio (SI)	0.8	0.6
Standard Deviation (SI)	15.1	14.5

Drawdowns & recovery

Period	Strategy	BSE 500
Resiliency during market correction (from September 2024 peak)	21.5%	-3.2%
Rebound from market lows (from March 2025 lows)	51.0%	18.8%

Faster revenue & earnings
growth than benchmark

Stronger ROE & minimal
leverage than benchmark

Cheaper PEG valuation
reflecting margin of safety

Outperformance with
less volatility

Disclaimer

This document has been prepared by Carnelian Asset Management & Advisors Private Limited ("Carnelian") and is provided to you for information only. This document does not constitute a prospectus, offer, invitation or solicitation and is not intended to provide the sole basis for any evaluation of the investment product or any other matters discussed in this document. This document is made available to you because Carnelian believes that you have sufficient knowledge, experience and/or professional advice to understand and make your own independent evaluation of the risks and rewards of the investments and/or other matters discussed in this document and to make your own independent decision whether to implement the same. Any view expressed in the document is generic and not a personal recommendation and/or advice. It does not consider your risk tolerance, financial situation, knowledge and experience. Please discuss with your investment advisor if you seek advice on whether the proposed investment product is appropriate for you. The investments discussed in this document may not be suitable for all investors. Investments are subject to market risk. There can be no assurance or guarantee that any investment will achieve any specific return. Unless expressly stated, product performances are not guaranteed by Carnelian or their affiliates or any government entity. Past performance figures are not verified by SEBI. Past performance is not necessarily an indicator of future performance. Actual results may vary significantly from the forward-looking statements contained in this presentation due to various risks and uncertainties, including the effect of economic and political conditions in India and outside India, volatility in interest rates and the securities market, new regulations and government policies that may impact the business of Carnelian as well as its ability to implement the strategy. The information contained in this document has been obtained from sources that Carnelian believes are reliable, but Carnelian does not represent or warrant that it is accurate or complete, and such information may be incomplete or condensed. Neither Carnelian, nor any affiliate, nor any of their respective officers, directors, partners, or employees accepts any liability whatsoever for any direct or consequential loss arising from any upon this document or its contents, or for any omission. The views in this document are generally those of Carnelian and are subject to change without notice, and Carnelian has no obligation to update its views or the information in this document. Carnelian or its affiliates may have acted upon or have made use of material in this document prior to its publication. Carnelian does not provide legal or tax advice and should you deem it necessary to obtain such advice, you should approach independent professional tax or legal advisors to obtain the same. This document is confidential and may not be reproduced or disclosed (in whole or part) to any other person without our prior written permission. The manner of distribution of this document and the availability of the products may be restricted by law or regulation in certain countries and persons who come into possession of this document are required to inform themselves of and observe such restrictions. This document is not directed to, nor intended for distribution or use by, any person or entity in any jurisdiction or country where the publication or availability of this document or such distribution or use would be contrary to local law or regulation, including for the avoidance of doubt the US. The contents of this document have not been reviewed by any regulatory authority in India or in any other jurisdiction. If you have any doubt about any of the contents of this document, you should obtain independent professional advice. The name of the strategy does not in any manner indicate the quality of the strategy, its future prospects or returns. The product strategies mentioned in the document may change depending upon the market conditions and the same may not be relevant in future. The sector(s)/stock(s)/issuer(s) mentioned in this document do not constitute any recommendation of the same and the strategy may or may not have any future position in these sector(s)/stock(s)/issuer(s). This strategy and this presentation have been prepared for potential investors in India and may not be published or distributed in the United States. This strategy does not constitute an offer of units for sale or the solicitation of any offer to buy Units in any jurisdiction, including the United States. Carnelian provides direct onboarding facility without any intermediary; investors may contact us at sales@carnelincapital.co.in for further information.